ライフサイエンスコーパス: nociceptin

1 eased, indicating an enhanced sensitivity to nociceptin.

2 Oddi (SO) were immunostained for orphanin FQ/nociceptin.

3 ted peptide (cgrp), galanin, hypocretin, and nociceptin.

4 induced increases in calcium was mimicked by nociceptin (0.1 microM).

5 Microinjections (30 nl) of nociceptin (0.15-0.62 mM) into the nCom elicited depress

6 eptors, into the nCom blocked the effects of nociceptin (0.31 mM, the maximally effective concentrati

7 Microinjections of nociceptin (0.31, 0.62, 1.25 and 2.25 mmol/L) into the n

8 a-receptors were labelled with [(3)H] leucyl-nociceptin (0.4 nM), [(3)H] DAMGO (4 nM), [(3)H] deltorp

9 e nociceptin antagonist [Phe1Psi(CH2NH)Gly2]-nociceptin(1-13) NH2 (NCA), a peptide that on its own ex

10 pseudopeptide, [Phe(1)iota(CH(2)-NH)Gly(2)]-nociceptin(1-13)-NH(2) (hereafter: [FG]N/OFQ(1-13)NH(2))

11 ion of the NOP selective antagonist [Nphe(1)]nociceptin(1-13)NH(2) elicits anxiety- and depression-li

12 The NOP antagonist [Nphe1]-nociceptin(1-13)NH2 increased the IPSP amplitudes in res

13 Application of [Nphe1]Nociceptin(1-13)NH2, a nociceptin receptor (NOP) antagon

14 L1 receptor antagonist, [Phe1Psi(CH2-NH)Gly2]Nociceptin(1-13)NH2.

15 Prior microinjections of [N-Phe(1)]-nociceptin-(1-13)-NH(2) (4.5 mM), a specific antagonist

16 blockade of nociceptin effects by [N-Phe(1)]-nociceptin-(1-13)-NH(2) and endomorphin-2 by naloxone, w

17 Nociceptin (100 nM-1 microM) potently inhibited the spon

18 We found that nociceptin (100-1000 nM) diminished basal-evoked compoun

19 Nociceptin (3 mg/kg, intraperitoneal) effectively inhibi

20 Nociceptin, a 17 amino acid opioid-like peptide that has

21 ough estrogen and progesterone regulation of nociceptin activity.

22 Also, the increased effectiveness of nociceptin after axotomy supports the hypothesis that it

23 hyl]-N,N -diethylbenzamide (SNC80)] or NOPR (nociceptin) agonists to inhibit forskolin-stimulated ade

24 Nociceptin also blocked the ethanol-induced augmentation

25 Nociceptin also prevented the ethanol-induced augmentati

26 Immunoreactivity for nociceptin, an endogenous ligand for the ORL1 opioid rec

27 eceptors also potentiated spinal orphanin FQ/nociceptin analgesia.

28 paration, we investigated the interaction of nociceptin and CRF on evoked and spontaneous GABAergic t

29 new evidence for an interaction between the nociceptin and CRF systems in the CeA.

30 Co-application of nociceptin and DADLE to neurons that were responsive to

31 Nociceptin and its receptor are widely distributed throu

32 To develop tools to study the function of nociceptin and NOP receptor, our research effort sought

33 Here, we identify the neuropeptides nociceptin and somatostatin, a neurotransmitter and neur

34 ( approximately 70%) were inhibited by both nociceptin and the delta-opioid receptor agonist, [D-ala

35 butions of orphanin FQ (OFQ/N; also known as nociceptin) and its cognate receptor, opioid receptor-li

36 matostatin controls ectodermal expression of nociceptin, and both peptides regulate Pax6 in lens and

37 Agonists for mu-opioid, nociceptin, and GABA(B) receptors induced postsynaptic c

38 The OFQ-activated current was blocked by the nociceptin antagonist [Phe1Psi(CH2NH)Gly2]-nociceptin(1-

39 Nociceptin appears to regulate a host of physiological f

40 start points for the transcription of prepro-nociceptin are identified by an 'oligoribonucleotide-cap

41 The present results identify nociceptin as a potent chemoattractant and provide a nov

42 ypothalamic membranes, utilizing [125I]Tyr12-nociceptin as ligand.

43 eous locomotor activity, whereas galanin and nociceptin attenuated these behaviors.

44 -RMTg infusion of the endogenous NOP agonist nociceptin attenuates the aversive behaviors in Post-EtO

45 approximately 50% decrease in [(3)H] leucyl-nociceptin binding was seen in heterozygous ORL1 mutant

46 Notably, nociceptin blocked the inhibition induced by acute ethan

47 cause the ORL-1 receptor agonist orphanin FQ/nociceptin blocks opioid-induced antinociception, we tes

48 ions of morphine and the opioid-like peptide nociceptin (both 1 mu) on dorsal root ganglion (DRG) neu

49 Nociceptin bound with picomolar affinity, dynorphin A wi

50 -bound deltaOR, dynorphin-bound kappaOR, and nociceptin-bound NOPR.

51 selectively responsive either to DADLE or to nociceptin, but not both.

52 In alert rats, i.c.v. injection of nociceptin caused a significant decrease in the gain of

53 The NOPR agonist, nociceptin, caused robust NOPR-YFP receptor internalizat

54 stigation provides preliminary evidence that nociceptin crosses the blood-brain barrier and shows upt

55 In neurons from ethanol-dependent animals, nociceptin decreased basal GABAergic transmission and bl

56 ma-aminobutyric acid (GABA) release, whereas nociceptin diminishes it.

57 In neurons from naive animals, nociceptin dose-dependently diminished basal-evoked GABA

58 The blockade of nociceptin effects by [N-Phe(1)]-nociceptin-(1-13)-NH(2)

59 When injected in murine air pouches, nociceptin elicited leukocyte infiltration in a concentr

60 Following highest i.t. dose of nociceptin employed (20 nmol), the gestational or sex st

61 Nociceptin evoked PMN chemotaxis with maximal activity a

62 Nociceptin exerts its antistress effect by counteracting

63 Here, we show that nociceptin-expressing neurons in the anterior bed nuclei

64 Unlike mice, orphanin FQ/nociceptin fails to elicit hyperalgesia in the rat follo

65 es to the exclusion of mammalian orphanin FQ/nociceptin from classic opioid ligands (i.e. F1Y and L14

66 , and specific binding with [(125)I]-labeled nociceptin gave an apparent K(d) approximately 1.5 nM fo

67 or the regulatory mechanisms of human prepro-nociceptin gene expression.

68 stream regulatory region of the human prepro-nociceptin gene has been cloned from adaptor-ligated gen

69 Our data suggest that nociceptin has a role in regulating the GABAergic system

70 , such as corticotropin-releasing factor and nociceptin, has been postulated to underlie relapse in a

71 ore the importance of the hormonal milieu to nociceptin hypoalgesic sensitivity.

72 e investigated the NMR solution structure of nociceptin in membrane-like environments (trifluoroethan

73 d calcium flux, alanine-scanning variants of nociceptin indicated that functionally important residue

74 Furthermore, hypocretin and nociceptin induced modality-specific differences in resp

75 The antagonist also blocked nociceptin-induced decreases in glutamatergic responses,

76 thanol-treated (ethanol-dependent) rats, the nociceptin-induced inhibition of evoked EPSP amplitude w

77 cute ethanol (44 mM) and ethanol blocked the nociceptin-induced inhibition of evoked EPSPs in CeA neu

78 ingly, in CeA of ethanol-dependent rats, the nociceptin-induced inhibition of IPSCs was increased, in

79 e 362, serine 363, and threonine 365 blocked nociceptin-induced internalization of NOPR.

80 We also found that nociceptin-induced NOPR-mediated JNK but not ERK signali

81 and the ORL-1 receptor agonist, orphanin FQ/nociceptin, induces analgesia at the spinal level, but a

82 ives of this study were to determine whether nociceptin inhibits acid-evoked cough in conscious anima

83 Nociceptin is an antistress neuropeptide in the brain th

84 sent in neural tissues and its activation by nociceptin is involved in the processing of pain signals

85 This hypoalgesic effect of nociceptin is not limited to attenuating the gestational

86 n rats, intrathecal (i.t.) administration of nociceptin is without effect on basal thresholds for res

87 channel current in axotomized DRG neurons by nociceptin led to a reduction in Ca2+-dependent K+ condu

88 dings demonstrate that endogenously released nociceptin may have a hitherto unexplored role in the fu

89 Thus, nociceptin may represent a therapeutic target for allevi

90 These properties of nociceptin may underlie its anti-alcohol and anxiolytic

91 We found that nociceptin moderately decreased IPSC amplitudes, acting

92 lanocortin (POMC) and pro-orphanin FQ (pOFQ)/nociceptin (N), in the brain.

93 bound conformation of the endogenous ligand, nociceptin (NC), several conformationally constrained an

94 Nociceptin (NCC, also known as FQ (N/OFQ)) is the 17-ami

95 Therefore, aBNST GABAergic nociceptin neurons may act as a gateway to feeding behav

96 drenaline (NA), and neuropeptides, including nociceptin (Noc), influence the excit ability of SG neur

97 f the mu (MOP), delta (DOP), kappa (KOP) and nociceptin (NOP) opioid peptide receptor genes have been

98 The nociceptin (NOP) receptor is a G-protein-coupled recepto

99 n between stress-promoting neuropeptides and nociceptin (NOP) receptors in humans.

100 adrenocorticotropic hormone 1-27 (ACTH) and nociceptin (NOP).

101 for the orphan opioid receptor, orphanin FQ/nociceptin (OFQ), has recently been characterized.

102 and the orphan receptor agonist orphanin FQ/nociceptin (OFQ).

103 The opioid peptide, Orphanin FQ/nociceptin (OFQ/N(1-17))(,) its active fragments, and a

104 Orphanin FQ/nociceptin (OFQ/N) and its receptor (ORL-1) have been pr

105 Orphanin FQ/nociceptin (OFQ/N) and its receptor share substantial st

106 n studies revealed expression of orphanin-FQ/nociceptin (OFQ/N) receptor (NOR) mRNA in the SCN, where

107 Orphanin FQ/nociceptin (OFQ/N) suppresses the activity of the dopami

108 Orphanin/nociceptin (OFQ/N), a 17-amino-acid peptide, is an endog

109 The heptadecapeptide, orphanin FQ/nociceptin (OFQ/N), binds with high affinity to the ORL-

110 Orphanin FQ/nociceptin (OFQ/N), the endogenous ligand for the ORL-1/

111 The heptadecapeptide orphanin FQ or nociceptin (OFQ/N), the endogenous ligand for the orphan

112 bles dynorphin, was named 'orphanin FQ' and 'nociceptin' (OFQ/N1-17).The OFQ/N1-17 receptor is expres

113 Nociceptin/OFQ (N/OFQ) is a 17 amino acid peptide that i

114 We tested the effect of nociceptin on acid-induced cough in conscious guinea pig

115 sults indicate that the inhibitory effect of nociceptin on acid-induced cough may result from a direc

116 preparation, we investigated the effects of nociceptin on glutamatergic transmission and its interac

117 Here, we investigated the effect of nociceptin on IPSCs in CeA neurons and its interaction w

118 on and explored the therapeutic potential of nociceptin opioid peptide (NOP) receptor agonism.

119 Activation of the nociceptin opioid peptide (NOP) receptor by its endogeno

120 ions as evidenced by the abrogation of N/OFQ-nociceptin opioid peptide (NOP) receptor signalling and

121 rea projecting RMTg neurons express Pnoc and nociceptin opioid peptide (NOP) receptors encoding gene

122 upled with moderate affinity and efficacy at nociceptin opioid peptide (NOP) receptors will have util

123 analyses provide a context for understanding nociceptin opioid peptide receptor (NOP) agonist pharmac

124 Agonists at the nociceptin opioid peptide receptor (NOP) are under inves

125 Nociceptin, which binds to the nociceptin opioid peptide receptor (NOP), regulates stre

126 n the two decades since the discovery of the nociceptin opioid receptor (NOP) and its ligand, nocicep

127 stituted piperdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to exp

128 Chemically diverse agonist ligands at the nociceptin opioid receptor G protein-coupled receptor sh

129 and identification of biased ligands at the nociceptin opioid receptor.

130 Nociceptin opposes CRF effects on CeA GABAergic transmis

131 Despite this, the spinal administration of nociceptin or agonists that activate ORL1 (opioid-like o

132 delta, and kappa opioid agonists as well as nociceptin or orphanin FQ (N/OFQ) peptide, an endogenous

133 rmine the role of the newly described opioid nociceptin orphanin FQ (NOC/oFQ) in such impaired dilati

134 e contribution of the newly described opioid nociceptin orphanin FQ (NOC/oFQ) to hypoxic-ischemic imp

135 Nociceptin (Orphanin FQ) is a newly discovered endogenou

136 The effects of nociceptin (orphanin FQ) on medial vestibular nucleus (M

137 High affinity and saturable nociceptin (orphanin FQ) receptors were detected and cha

138 nd brain antistress systems (neuropeptide Y, nociceptin [orphanin FQ]) in drug dependence, with empha

139 ole of carboxyl-terminal regulation of NOPR (nociceptin, orphanin FQ receptor) signaling and function

140 In contrast, enkephalins (100-1000 nmol) and nociceptin-orphanin FQ (3-30 nmol) only inhibit pain wit

141 f ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist ac

142 peptide systems have attracted interest, the nociceptin/orphanin FQ (N/OFQ) and orexin/hypocretin (Or

143 tide (NOP) receptor by its endogenous ligand Nociceptin/Orphanin FQ (N/OFQ) attenuates alcohol drinki

144 Nociceptin/orphanin FQ (N/OFQ) controls different biolog

145 Although nociceptin/orphanin FQ (N/OFQ) influences dopamine (DA)

146 Nociceptin/orphanin FQ (N/OFQ) is an antistress neuropep

147 Nociceptin/orphanin FQ (N/OFQ) is an endogenous ligand o

148 Nociceptin/Orphanin FQ (N/OFQ) is an endogenous ligand o

149 Nociceptin/orphanin FQ (N/OFQ) is the endogenous ligand

150 an drive a negative affective state and that nociceptin/orphanin FQ (N/OFQ) may play a role in affect

151 The nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor is

152 p between neuropsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor.

153 ing of natively and heterologously expressed nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptors w

154 logical criteria in the 1970s and 1980s, the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP, al

155 implicated the hypocretin/orexin (Hcrt) and nociceptin/orphanin FQ (N/OFQ) peptidergic systems in th

156 The neuropeptide nociceptin/orphanin FQ (N/OFQ) plays a key role in regul

157 he primary mediator of stress responses, and nociceptin/orphanin FQ (N/OFQ) plays an important role i

158 Nociceptin/orphanin FQ (N/OFQ) promotes increased energy

159 tudies have suggested that activation of the Nociceptin/orphanin FQ (N/OFQ) receptor (NOPR) reduces l

160 this issue, we evaluated whether blockade of nociceptin/orphanin FQ (N/OFQ) tone potentiated the anti

161 Nociceptin/orphanin FQ (N/OFQ), an endogenous opioid neu

162 cistatin, a product of the same precursor as nociceptin/orphanin FQ (N/OFQ), has been shown to antago

163 udy we investigated whether the neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in

164 Nociceptin/orphanin FQ (N/OFQ), the endogenous agonist f

165 gulates an opioid-related neuropeptide named Nociceptin/Orphanin FQ (N/OFQ), the ligand of the G prot

166 lized to the efficacy of the natural agonist nociceptin/orphanin FQ (N/OFQ), we found that different

167 Since its discovery, the nociceptin/orphanin FQ (N/OFQ)-NOP receptor system has b

168 sible biologically active conformation(s) of nociceptin/orphanin FQ (N/OFQ).

169 The nociceptin/orphanin FQ (N/OFQ)/N/OFQ receptor (NOP) syst

170 The opiate-like peptide nociceptin/orphanin FQ (Noc) and its receptor [opiate re

171 tery dilation to the newly described opioid, nociceptin/orphanin FQ (NOC/oFQ) following hypoxia/ische

172 Nociceptin/orphanin FQ (NOC/oFQ) is a recently discovere

173 tery dilation to the newly described opioid, nociceptin/orphanin FQ (NOC/oFQ), following hypoxia/isch

174 elevates the CSF concentration of the opioid nociceptin/orphanin FQ (NOC/oFQ), which contributes to i

175 Corticotropin-releasing factor (CRF) and nociceptin/orphanin FQ (nociceptin) regulate ethanol int

176 ates several addiction-related processes and nociceptin/orphanin FQ (nociceptin) regulates ethanol in

177 Opioid peptides and nociceptin/orphanin FQ (nociceptin) within the CeA are i

178 ulating brain receptors for the neuropeptide nociceptin/orphanin FQ (NOP) can decrease ethanol drinki

179 The nociceptin/orphanin FQ (NOP) receptor, the fourth member

180 Nociceptin/orphanin FQ (NOP/OFQ) is the endogenous ligan

181 Nociceptin/orphanin FQ is a recently discovered neuropep

182 Agonists of the nociceptin/orphanin FQ opioid peptide (NOP) receptor, a

183 The nociceptin/orphanin FQ opioid peptide receptor (NOPr) is

184 significant colocalization with MCH neurons: nociceptin/orphanin FQ opioid receptor (NOP), MCHR1, bot

185 Here we examine biased signaling at the nociceptin/orphanin FQ opioid receptor (NOPR), the most

186 The superfusion of CeA slices with nociceptin/orphanin FQ peptide (N/OFQ; 500 nM), an endog

187 n following activation of the adrenergic and nociceptin/orphanin FQ peptide (NOP) opioid receptors, r

188 Nociceptin/orphanin FQ peptide (NOP) receptor is a new c

189 e transmitter nociceptin, which binds to the nociceptin/orphanin FQ peptide (NOP) receptor, is a core

190 de ((11)C-NOP-1A), a new radioligand for the nociceptin/orphanin FQ peptide (NOP) receptor, with high

191 50 = 1.6 and 4.1 nM, respectively) at human nociceptin/orphanin FQ peptide (NOP) receptors.

192 lase (AC) by agonists to delta-opioid (DOR), nociceptin/orphanin FQ peptide (NOPr), alpha2-adrenergic

193 totypical bifunctional ligands targeting the nociceptin/orphanin FQ peptide receptor (NOP) and u-opio

194 st in its activities at the kappa opioid and nociceptin/orphanin FQ peptide receptors.

195 affinity at the fourth opioid receptor, the nociceptin/orphanin FQ receptor (NOP).

196 pharmacodynamics, morphine metabolites, the nociceptin/orphanin FQ receptor system, acute opioid tol

197 ke receptor (ORL1) and its endogenous ligand nociceptin/orphanin FQ, which displayed anti-opioid prop

198 Nociceptin/orphanin-FQ (N/OFQ) is a recently appreciated

199 and partial agonist sunobinop activates the nociceptin/orphanin-FQ peptide receptor and promotes non

200 ceptin opioid receptor (NOP) and its ligand, nociceptin/orphaninFQ (N/OFQ), steady progress has been

201 Here, we dissected the role of a nociceptin peptide circuit in reward seeking.

202 tered intracerebroventricularly, orphanin FQ/nociceptin produces hyperalgesia and/or reverses opioid

203 The nociceptin receptor (Noci-R) is a G protein-coupled rece

204 Application of [Nphe1]Nociceptin(1-13)NH2, a nociceptin receptor (NOP) antagonist, revealed tonic inh

205 were discovered as a new structural class of nociceptin receptor (NOP) ligands.

206 on ablation, inhibition, and conditional VTA nociceptin receptor (NOPR) deletion increased operant re

207 l and anxiolytic properties and identify the nociceptin receptor as a useful therapeutic target for a

208 e searches, affording hits with demonstrated nociceptin receptor binding affinities.

209 d receptor genes including delta, kappa, and nociceptin receptor genes produced similar circRNAs.

210 st recent addition to the opioid family, the nociceptin receptor system, shows promise as the missing

211 ve been synthesized and shown to bind to the nociceptin receptor with high affinity.

212 , and kappa opioid receptors and the related nociceptin receptor, ORL1, each couple to Galphaqi5, Gal

213 the link comes from mutant mice lacking the nociceptin receptor, which show improved learning and me

214 tor (kappa-OR), but it is ineffective at the nociceptin receptor.

215 the opioid receptors and antagonists at the nociceptin receptor.

216 H2 (7) was linked to peptide ligands for the nociceptin receptor.

217 receptors (MORs and DORs, respectively) and nociceptin receptors (NOPRs).

218 Decreased midbrain and cerebellum nociceptin receptors are associated with less severe PTS

219 y was used to measure the in vivo binding to nociceptin receptors in 18 college women who had experie

220 s support a role for medications that target nociceptin receptors in the treatment of alcohol use dis

221 ing factor (CRF) and nociceptin/orphanin FQ (nociceptin) regulate ethanol intake and anxiety-like beh

222 elated processes and nociceptin/orphanin FQ (nociceptin) regulates ethanol intake and anxiety-like be

223 Nociceptin selectively inhibited only the sustained comp

224 Medications that target nociceptin should be explored to prevent and treat PTSD.

225 Consequently, loss of somatostatin and nociceptin signaling leads to severe reduction of lens f

226 Furthermore, intra-RMTg infusion of nociceptin significantly reduces alcohol consumption.

227 Nociceptin-stimulated PMN infiltration was inhibited by

228 ntake and relapse, including the urocortins, nociceptin, substance P, and neuropeptide S.

229 olds are elevated by approximately 70%, i.t. nociceptin substantially attenuates jump thresholds in a

230 e studies implicate a potential role for the nociceptin system in regulating glutamatergic transmissi

231 gmental area producing the endogenous opioid nociceptin that regulates dopamine neuron firing and act

232 of spinal nociceptive pathways that utilize nociceptin to the etiology of extraordinary painful preg

233 s by forskolin treatment up-regulates prepro-nociceptin transcription.

234 does not necessarily rule out alterations in nociceptin transmission in alcohol dependence.

235 The effect of nociceptin was antagonized by naloxone benzoylhydrazone

236 U69593) was unchanged, whereas the effect of nociceptin was increased.

237 onstant was significant even at low doses of nociceptin which did not cause other observable behaviou

238 id receptor-like receptor ORL(1) (orphaninFQ/nociceptin) which may mediate nociceptive or antinocicep

239 Nociceptin, which binds to the nociceptin opioid peptide

240 The neuropeptide transmitter nociceptin, which binds to the nociceptin/orphanin FQ pe

241 that both these cell types are responsive to nociceptin, which induced membrane hyperpolarisation and

242 ioid receptors) did not block the effects of nociceptin, while it did block the effects of endomorphi

243 pression of the peptidergic neurotransmitter nociceptin, while minimally affecting the expression of

244 Opioid peptides and nociceptin/orphanin FQ (nociceptin) within the CeA are implicated also in regula